Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of immunotherapies to treat cancer.
Redwood City, CA
Joined February 2017
- Tweets696
- Following174
- Followers3.8K
- Likes11
Coherus Oncology retweeted
Dr. @NguyenAlana from @WeillCornell presents the rationale for combining KRAS inhibition with CCR8-targeted therapy: mutant KRAS promotes suppressive Tregs, while KRAS blockade can recruit Tregs that blunt response. Selective CCR8+ Treg depletion may enhance efficacy #DAVAGI
P y reported Q3 2025 financial results today. Join us for a conference call and webcast where the $CHRS executive team will discuss Q3 2025 financial results and recent business highlights starting at 5 pm ET. Webcast: bit.ly/47jYekQ
Coherus Oncology will report Q3 2025 financial results on November 6, 2025. Starting at 5 pm EDT, the $CHRS executive team will host a conference call and webcast to discuss Q3 2025 financial results and recent business highlights. Webcast: bit.ly/47jYekQ
Coherus Oncology is attending the following Investor Conferences in November and December. For webcast links of our presentations, please visit: bit.ly/4nhV8EB
To schedule 1:1 meetings during the conference, please reach out to your respective bank representative.
Attending Opal Group's Family Office and Private Wealth Management Forum? Don't miss Coherus Oncology's CEO Denny Lanfear's presentation tomorrow and meet with the Coherus Oncology team.
We are excited to participate in SITC’s Targets for Cancer IO webinar and discuss CCR8 as a therapeutic target in oncology and share our clinical experience with CHS-114, our highly selective cytolytic anti-CCR8 mAb. Register to attend: bit.ly/3VEkGjx
Tune in on Oct. 22 for our Development of Anti-CCR8 Ab - Mechanisms and Clinical Results Webinar! We will address the novel therapeutic target C-C chemokine receptor 8 (CCR8), its role in regulatory T cell (Treg) activity and immunosuppression.
Register: sitcancer.org/edu/webinars/t…
We look forward to sharing new biomarker data from our Phase 1 study of CHS-114 at the 40th Annual SITC Meeting in November. Read more about our presentation and upcoming SITC webinar: bit.ly/3VJT1h5
Tune in tomorrow for our fireside chat at UBS’s Virtual Oncology Day. We will discuss the latest developments with our novel oncology pipeline targeting the immune-suppressive mechanisms in the TME. Listen to the webcast: bit.ly/4mCSzvR
We’re proud to have partnered with NORD and Rep Mike Kelly (PA) to introduce a resolution recognizing Sept 30th as Rare Cancer Day. Join us in supporting patients & families affected by a cancer diagnosis, including those with a rare form. Learn more: bit.ly/4gJMvR8
Coherus Oncology’s CEO, Denny Lanfear, and Chief Scientific and Development Officer, Theresa LaVallee, are participating in a fireside chat with Douglas Tsao at the H.C. Wainwright 27th Annual Global Investment Conference today. Listen to the webcast here: bit.ly/46sQtdc
Coherus Oncology’s CEO, Denny Lanfear, and Chief Scientific and Development Officer, Theresa LaVallee, are participating in a fireside chat with Colleen Kusy at the Baird 2025 Global Healthcare Conference today. Listen to the webcast here: bit.ly/3Ie3UV6
Coherus Oncology is attending the following Fall Investor Conferences. For webcast links of our presentations, please visit: bit.ly/4nhV8EB
To schedule 1x1 meetings during the conferences, please reach out to your respective bank representative.
Join us for our Q2 2025 earnings call today, starting at 5:00 p.m. ET, to hear about our Q2 financial results and business highlights. Press release: bit.ly/4mBp0vl and listen to the webcast: bit.ly/4fgZxVu
Coherus Oncology will report Q2 2025 financial results on August 7, 2025. Starting at 5 pm EDT, the $CHRS executive team will host a conference call and webcast to discuss Q2 2025 financial results and recent business highlights. Webcast: bit.ly/4fgZxVu
Attending #ASCO25? Come by Booth #11081 this weekend to meet the Coherus team and learn more about our products and innovative immuno-oncology pipeline.
Starting today, we are now Coherus Oncology, Inc. Our new name better reflects our strategic transformation to focus exclusively on innovative cancer therapeutics. Read more here: bit.ly/3SsBGHO
Join us for our Q1 2025 earnings call today, starting at 5:00 p.m. ET, to hear about our Q1 financial results and business highlights. Read our press release: bit.ly/4dob708 and listen to the webcast: bit.ly/3EOEHyY $CHRS
Coherus will report Q1 2025 financial results on May 12, 2025. Starting at 5 pm EDT, $CHRS executive team will host a conference call and webcast to discuss Q1 2025 financial results and recent business highlights. Webcast: bit.ly/3EOEHyY
Breaking News: Coherus completes strategic transformation with successful divestiture of UDENYCA® franchise. Read our press release for more: bit.ly/3XWNZ2d
We look forward to presenting interim data from our Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and with toripalimab in patients with HNSCC at the 2025 AACR Annual Meeting. For details: bit.ly/41IWvnO
